Entera Bio plans Phase 3 registrational trial of EB613 oral osteoporosis tablet
Bitget2026/10/08 12:03Entera Bio announced a late-breaking ASBMR 2026 poster detailing the planned Phase 3 registrational trial design for EB613, an oral osteoporosis therapy. The Phase 3 design will be presented on Oct. 11, 2026, outlining how the single randomized, double-blind, placebo-controlled study will evaluate EB613. Phase 2 EB613 findings were already selected for presentation at the same meeting, highlighting anabolic effects in high-fracture-risk postmenopausal osteoporosis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9839991) on October 08, 2026, and is solely responsible for the information contained therein.
- Entera Bio announced a late-breaking ASBMR 2026 poster detailing the planned Phase 3 registrational trial design for EB613, an oral osteoporosis therapy.
- The Phase 3 design will be presented on Oct. 11, 2026, outlining how the single randomized, double-blind, placebo-controlled study will evaluate EB613.
- Phase 2 EB613 findings were already selected for presentation at the same meeting, highlighting anabolic effects in high-fracture-risk postmenopausal osteoporosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
